479485d3692ab15b230f77907feeb1e74d926e4b4f6f173bfd02fecb71efdb00  ./Abstract.md
187181a20d9e119320bcd3080ce4e850499e20a612dc43d0205f8360db6683e7  ./CHECKSUMS.sha256
2bffce8be2b74b9abf0f142fd57725ddd1499b999ddab3c1104b621447bf17fe  ./Discussion.md
bcc99a79bb4dc23b90e658f717b3edd7ff8bd2a452fc5d56b8689e57f73baf6b  ./SUBMISSION_PACKAGE.md
599c71d61cdb3bd7e43179f24415f89d1a9a8c527d7954154185f0f12c638b81  ./data/guide_validation_dataset.csv
6034ebc9e03a6ee98c13641d74d1359e5d0813d30f7fca153684dc702cdea520  ./data/guide_validation_dataset.json
1dc5d77ed031ce27c4cd624c208e73538ab2ada995bf6a7ee6d89e75bf2ba09f  ./data/real_guide_validation_dataset.csv
790956185a77dde66057e7aaae7db6fd5f505f0bda819d8959d728219e719341  ./data/real_guide_validation_dataset.json
6a872bf1cd811b43834dbf9442081fbb398c4cdb73fdbdd75c88a8f5262a721b  ./data/real_target_lock_data.csv
db86d79c18bd745a02f78635210cfad157d5b1e9b0d416b4ecc9a4eaed562571  ./data/real_target_lock_data.json
7df162815d1b426b382c000779dcef1a17fb27affb54a5fec0e507c0a09523cb  ./data/target_lock_heatmap_data.csv
614aba6a9b33b632d91f686080dc627eca1ea2a41575c0e6ab45b11b96d4d3ef  ./data/target_lock_heatmap_data.json
7be79885263916d7f2e7d84e3c66e313b014cbd4291f52349a4843415cbf893d  ./environment.yml
6617f34c1f890317dba79922eac8a8ae29f6c7f2251ddb8798ae1ecf58529908  ./figures/F2_REAL_target_lock_heatmap.png
07564e09f28e7ff7e30ac03ebb3f02709d00fa2db2024562d0846ca0830282e9  ./figures/F2_REAL_target_lock_heatmap.svg
c7fe0776065d588e3b70a036e94e66d2fd0cf0948adb89ade68709ae252d7caf  ./figures/F2_supp_component_scores.png
5d0944129977624a28de426a97453e2800a10f1119ad8b3be57867dd7dc48959  ./figures/F2_supp_component_scores.svg
85ba9dd5685f867ec55edbfd73784668288d97480c73d0cb390aa84f34c9866e  ./figures/F2_target_lock_heatmap.png
2bfa4b9ae897d5b1fcc5fa624a3ddc539b7d600e78575636cd254316cfc07dc9  ./figures/F2_target_lock_heatmap.svg
21a1ca6b8174fe3a7e938da18ea6eb5dfbe1a9f8190344d17aa1527da8f0ce36  ./figures/F3_efficacy_distribution.png
3940802cdc1d40b61729e4cd16073becb00b9e790bbb4bdc9de57fceeda58d2c  ./figures/F3_efficacy_distribution.svg
96362240ad62f69c88ef4fd5c9033038b8e62ea57a1f42e01d8a9574268c4da4  ./figures/F4_safety_distribution.png
c1cd5181f08cb90b6f81d8157f38f88ad4e7c7c31f429eb4b84e832eee05ad27  ./figures/F4_safety_distribution.svg
ee69dfb032835d18206db8972dafd55730e0b97703e64db2c165194a55b3ed73  ./figures/F5_assassin_score_distribution.png
45a97ca5cdc52ece46f9ca644ccb915ebe2737ad2272f76a19086c8e0d04072e  ./figures/F5_assassin_score_distribution.svg
fc609f979caccdb61946d3a475f25750b70702e6a039c6b2fc943b4ca509f75c  ./figures/LEGENDS.md
9f5d61cd0a9e0f2c0292a593473964aa94f8bfee34e43e8acf14b34b7aec1d51  ./methods/Methods.md
f8280c89c8994567a870b9b52f12274a3b1c70b387cf6ff54185276a22ad9bcf  ./tables/table2_performance_metrics.csv
11a158daff35d30280250ae12f05b623cb46ea5f96377377873b855a5c9dcc03  ./tables/table2_performance_metrics.tex
